ProductsPricingFree Market DashboardMarket News FeedScannerChartsHeatmapMarket SectorsTrack RecordMAD AcademyMCP Connector

BridgeBio Pharma, Inc. (BBIO)

Nasdaq · Common stock · Pharmaceutical Preparations

$68.57+1.02 (+1.51%)

As of Oct 21, 2:18 PM ET15 min delayedAbout 15 minutes behind the market. Every member plan is real time.

Follow BBIO in real time

Real-time quotes, Pro Charting, the scanner and the alert feed on BBIO and every other US listing.

Start 5 days free

Try Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.

Or open the free BBIO chart →

BBIO at a glance

Key statistics

$13.21B

Market capitalization

Previous close
$67.55
Open
$68.05
Day range
$67.54 – $68.79
Volume
1.83M
Average volume (30 sessions)
2.90M
Shares outstanding
195.49M
Earnings per share
$(3.54)
Price / sales
18.5
Beta (1 year, vs SPY)
1.13

Where the price sits in its year

52-week range

39% of the range

Below the 52-week high
-26.6%
Above the 52-week low
+30.0%

Completed sessions through Oct 20, 2026

Technical snapshot

Below its 50-day and 200-day averages

20-day average
$66.15+2.1%
50-day average
$72.27-6.5%
200-day average
$72.98-7.4%
RSI (14)48.5

Between the conventional 30 and 70 bands.

+6.7%

1 week

+1.5%

1 month

-18.3%

3 months

-11.7%

Year to date

+23.0%

1 year

Price change over each window, from completed sessions. Past performance does not indicate future results.

Every plan: MACD, ATR, the 20- and 50-day ranges, five-year and all-history extremes and the full indicator set, live on Pro Charting.

The member platform, in real time

What members do with BBIO

Every plan

BBIO on Pro Charting

Every intraday interval in real time, the drawing kit and the full set of technical studies on BBIO.

See the plans →

Every plan

Screen names like BBIO

The real-time scanner: price, volume, technical, fundamental and chart-pattern filters across the whole US market.

See the plans →

Analysis Tools Only

Set a price line on BBIO

Put BBIO on your watchlist, draw the levels you care about, and My Dashboard tracks where it trades against them.

See the plans →

Stock Alerts + Tools

Open alerts on BBIO

See whether there is an open premium alert on BBIO, with its entry, stop and exit, each one reviewed by an analyst before it is sent.

See the plans →

From the public news wire

BBIO headlines

Market news →

SEC Form 4, most recent first

Insider filings

How to read these →

  • Kumar Neil

    −8.7K

    Chief Executive Officer, Director · Open-market sale

    $601.87K · Sep 17, 2026

  • Kumar Neil

    −1.3K

    Chief Executive Officer, Director · Open-market sale

    $88.98K · Sep 17, 2026

  • Kumar Neil

    −8.1K

    Chief Executive Officer, Director · Open-market sale

    $679.26K · Aug 19, 2026

  • Kumar Neil

    −1.2K

    Chief Executive Officer, Director · Open-market sale

    $100.44K · Aug 18, 2026

  • Kumar Neil

    −14.6K

    Chief Executive Officer, Director · Open-market sale

    $1.21M · Aug 18, 2026

  • Kumar Neil

    −1.9K

    Chief Executive Officer, Director · Open-market sale

    $154.18K · Aug 18, 2026

  • Kumar Neil

    −17.3K

    Chief Executive Officer, Director · Open-market sale

    $1.42M · Aug 18, 2026

  • Kumar Neil

    −100

    Chief Executive Officer, Director · Open-market sale

    $8.56K · Aug 19, 2026

About BridgeBio Pharma, Inc.

BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. Its key drug is Attruby (acoramidis), an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.

Exchange
Nasdaq
Security
Common stock
Industry
Pharmaceutical Preparations
Headquarters
Palo Alto, CA
Employees
839
Listed since
Jun 27, 2019
Website
bridgebio.com
Educational content only. MadStockAlerts provides market commentary, research, and educational content. It is not personalized investment advice, and nothing here is a recommendation to buy or sell any security. Trading and investing involve substantial risk, including loss of capital. See the Risk Disclosure and Customer Agreement.

Pick the desk that fits how you trade

Analysis Tools Only for the real-time scanner, Pro Charting and the research desk. Stock Alerts + Tools for the human-reviewed alert feed. Premium Membership for both, at one price.

Start 5 days free

Try Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.

Other plans from $39 a month. Pay by card, Apple Pay, Google Pay, Link, Cash App Pay or Amazon Pay through Stripe.